• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Atherosclerosis Partnering 2009-2014 Product Image

Atherosclerosis Partnering 2009-2014

  • Published: August 2014
  • Region: Global
  • 100 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

Atherosclerosis Partnering 2009-2014 provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of atherosclerosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors atherosclerosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 25 links to online copies of actual atherosclerosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in atherosclerosis partnering

2.1. Introduction
2.2. Atherosclerosis partnering over the years
2.3. Bigpharma atherosclerosis dealmaking activity
2.4. Atherosclerosis partnering by deal type
2.5. Atherosclerosis partnering industry sector
2.6. Atherosclerosis partnering by stage of development
2.7. Atherosclerosis partnering by technology type
2.8. Disclosed financial deal terms for atherosclerosis partnering
2.8.1 Atherosclerosis headline values
2.8.2 Atherosclerosis upfront payments
2.8.3 Atherosclerosis milestone payments
2.8.4 Atherosclerosis royalty rates
Chapter 3 – Leading atherosclerosis deals

3.1. Introduction
3.2. Top atherosclerosis deals by value
3.3. Top atherosclerosis deals involving bigpharma
Chapter 4 – Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
Chapter 5 – Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices

Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures

Figure 1: Atherosclerosis partnering since 2009
Figure 2: Bigpharma – top 50 – atherosclerosis deals 2009 to 2011
Figure 3: Bigpharma atherosclerosis deal frequency – 2009 to 2011
Figure 4: Atherosclerosis partnering by deal type since 2009
Figure 5: Atherosclerosis partnering by industry sector since 2009
Figure 6: Atherosclerosis partnering by stage of development since 2009
Figure 7: Atherosclerosis partnering by technology type since 2009
Figure 8: Atherosclerosis deals with a headline value
Figure 9: Atherosclerosis deals with upfront payment values
Figure 10: Atherosclerosis deals with milestone payments
Figure 11: Atherosclerosis deals with royalty rates, %
Figure 12: Top atherosclerosis deals by value since 2009
Figure 13: Top atherosclerosis deals signed by bigpharma value since 2009
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos